214 related articles for article (PubMed ID: 25776745)
1. Nonreplicating, cyst-defective type II Toxoplasma gondii vaccine strains stimulate protective immunity against acute and chronic infection.
Fox BA; Bzik DJ
Infect Immun; 2015 May; 83(5):2148-55. PubMed ID: 25776745
[TBL] [Abstract][Full Text] [Related]
2. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii.
Fox BA; Bzik DJ
Infect Immun; 2010 Sep; 78(9):3744-52. PubMed ID: 20605980
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain.
Gigley JP; Fox BA; Bzik DJ
Infect Immun; 2009 Dec; 77(12):5380-8. PubMed ID: 19797073
[TBL] [Abstract][Full Text] [Related]
4. A Toxoplasma gondii vaccine encoding multistage antigens in conjunction with ubiquitin confers protective immunity to BALB/c mice against parasite infection.
Yin H; Zhao L; Wang T; Zhou H; He S; Cong H
Parasit Vectors; 2015 Sep; 8():498. PubMed ID: 26420606
[TBL] [Abstract][Full Text] [Related]
5. DNA immunization with eukaryotic initiation factor-2α of Toxoplasma gondii induces protective immunity against acute and chronic toxoplasmosis in mice.
Chen J; Huang SY; Zhou DH; Li ZY; Petersen E; Song HQ; Zhu XQ
Vaccine; 2013 Dec; 31(52):6225-31. PubMed ID: 24183979
[TBL] [Abstract][Full Text] [Related]
6. Live Attenuated Pru:Δcdpk2 Strain of Toxoplasma gondii Protects Against Acute, Chronic, and Congenital Toxoplasmosis.
Wang JL; Li TT; Elsheikha HM; Chen K; Cong W; Yang WB; Bai MJ; Huang SY; Zhu XQ
J Infect Dis; 2018 Jul; 218(5):768-777. PubMed ID: 29669003
[TBL] [Abstract][Full Text] [Related]
7. Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.
Fox BA; Sanders KL; Chen S; Bzik DJ
Trends Parasitol; 2013 Sep; 29(9):431-7. PubMed ID: 23928100
[TBL] [Abstract][Full Text] [Related]
8. Toxoplasma gondii: protective immunity induced by rhoptry protein 9 (TgROP9) against acute toxoplasmosis.
Chen J; Zhou DH; Li ZY; Petersen E; Huang SY; Song HQ; Zhu XQ
Exp Parasitol; 2014 Apr; 139():42-8. PubMed ID: 24602875
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Protective Immune Responses Induced by Recombinant TrxLp and ENO2 Proteins against
Wang M; Yang XY; Zhang NZ; Zhang DL; Zhu XQ
Biomed Res Int; 2016; 2016():3571962. PubMed ID: 27803923
[No Abstract] [Full Text] [Related]
10. Cell-mediated immunity to Toxoplasma gondii develops primarily by local Th1 host immune responses in the absence of parasite replication.
Gigley JP; Fox BA; Bzik DJ
J Immunol; 2009 Jan; 182(2):1069-78. PubMed ID: 19124750
[TBL] [Abstract][Full Text] [Related]
11. Co-administration of interleukins 7 and 15 with DNA vaccine improves protective immunity against Toxoplasma gondii.
Chen J; Li ZY; Petersen E; Liu WG; Zhu XQ
Exp Parasitol; 2016 Mar; 162():18-23. PubMed ID: 26706605
[TBL] [Abstract][Full Text] [Related]
12. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice.
Qu D; Wang S; Cai W; Du A
Vaccine; 2008 Aug; 26(35):4541-8. PubMed ID: 18590785
[TBL] [Abstract][Full Text] [Related]
13. IL-15 prolongs the duration of CD8+ T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii.
Khan IA; Casciotti L
J Immunol; 1999 Oct; 163(8):4503-9. PubMed ID: 10510393
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in developing vaccines against Toxoplasma gondii: an update.
Zhang NZ; Wang M; Xu Y; Petersen E; Zhu XQ
Expert Rev Vaccines; 2015; 14(12):1609-21. PubMed ID: 26467840
[TBL] [Abstract][Full Text] [Related]
15. Vaccines against Toxoplasma gondii: challenges and opportunities.
Jongert E; Roberts CW; Gargano N; Förster-Waldl E; Petersen E
Mem Inst Oswaldo Cruz; 2009 Mar; 104(2):252-66. PubMed ID: 19430651
[TBL] [Abstract][Full Text] [Related]
16. The location of invasion-related protein MIC3 of Toxoplasma gondii and protective effect of its DNA vaccine in mice.
Xiang W; Qiong Z; Li-peng L; Kui T; Jian-wu G; Heng-ping S
Vet Parasitol; 2009 Dec; 166(1-2):1-7. PubMed ID: 19800170
[TBL] [Abstract][Full Text] [Related]
17. A heterologous prime-boost vaccination regime using DNA and a vaccinia virus, both expressing GRA4, induced protective immunity against Toxoplasma gondii infection in mice.
Zhang G; Huong VT; Battur B; Zhou J; Zhang H; Liao M; Kawase O; Lee EG; Dautu G; Igarashi M; Nishikawa Y; Xuan X
Parasitology; 2007 Sep; 134(Pt 10):1339-46. PubMed ID: 17506929
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with replication-deficient recombinant adenoviruses encoding the main surface antigens of toxoplasma gondii induces immune response and protection against infection in mice.
Caetano BC; Bruña-Romero O; Fux B; Mendes EA; Penido ML; Gazzinelli RT
Hum Gene Ther; 2006 Apr; 17(4):415-26. PubMed ID: 16610929
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of three recombinant multi-antigenic vaccines composed of surface and secretory antigens of Toxoplasma gondii in murine models of experimental toxoplasmosis.
Dziadek B; Gatkowska J; Brzostek A; Dziadek J; Dzitko K; Grzybowski M; Dlugonska H
Vaccine; 2011 Jan; 29(4):821-30. PubMed ID: 21087690
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of two novel DNA vaccines expressing Toxoplasma gondii rhomboid 4 and rhomboid 5 proteins against acute and chronic toxoplasmosis in mice.
Zhang NZ; Xu Y; Wang M; Petersen E; Chen J; Huang SY; Zhu XQ
Expert Rev Vaccines; 2015; 14(9):1289-97. PubMed ID: 26111968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
